Menostar: Critical Product Identification Error
Menostar is NOT human menopausal gonadotropin (hMG) for ovarian stimulation—it is an estradiol transdermal patch (14 mcg/day) indicated solely for prevention of postmenopausal osteoporosis. This is a fundamental medication safety issue that must be clarified immediately 1.
What Menostar Actually Is
Menostar is a low-dose estradiol transdermal system delivering 14 mcg of estradiol per day via a 3.25 cm² patch containing 1 mg total estradiol 1.
Approved Indication
- Prevention of postmenopausal osteoporosis only 1
- Should only be considered for women at significant risk of osteoporosis when non-estrogen medications have been evaluated first 1
Dosing Regimen
- Apply one patch to clean, dry area of lower abdomen or upper buttock once weekly 1
- Rotate application sites with minimum 1-week interval between same site 1
- Do NOT apply to or near breasts 1
- Use lowest effective dose for shortest duration consistent with treatment goals 1
Contraindications (Absolute)
- Undiagnosed abnormal genital bleeding 1
- Breast cancer (current or history) 1
- Estrogen-dependent neoplasia 1
- Active or history of DVT/PE 1
- Active or history of arterial thromboembolic disease (stroke, MI) 1
- Known hypersensitivity/anaphylaxis/angioedema to Menostar 1
- Hepatic impairment or disease 1
- Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders 1
Critical Safety Warnings
Cardiovascular risks: Estrogen-alone therapy increases risk of stroke and DVT. Immediately discontinue if these occur or are suspected 1.
Endometrial cancer risk: Women with intact uterus generally require progestogen addition to reduce endometrial cancer risk. Women without uterus do not need progestogen unless they have history of endometriosis 1.
Monitoring Requirements
- Periodic reevaluation to determine if treatment remains necessary 1
- Manage cardiovascular risk factors (hypertension, diabetes, tobacco use, hypercholesterolemia, obesity) 1
- Manage VTE risk factors (personal/family history of VTE, obesity, systemic lupus erythematosus) 1
If You Need hMG for Ovarian Stimulation
For actual ovarian stimulation in IVF/ICSI, hMG is equally recommended to recombinant FSH (r-hFSH) with a conventional starting dose of 150-225 IU 2. The 2026 ESHRE guidelines provide strong evidence that hMG and r-hFSH have equivalent efficacy for ovarian stimulation 2.
Key Points for hMG in Ovarian Stimulation
- Conventional gonadotropin dosing: 150-225 IU 2
- Combining r-hFSH with hMG (either from start or mid-phase) is probably NOT recommended over using either alone in normal and low responders 2
- In women with predicted high response using short GnRH antagonist protocols, hMG may reduce OHSS compared with rFSH 3
This distinction between Menostar (estrogen patch) and hMG (gonadotropin for fertility) is critical for patient safety.